Source: Pharamceutical Technology

Forbius: BMS agrees to acquire biotherapeutics developer Forbius

Bristol Myers Squibb (BMS) has agreed to acquire Forbius, a protein engineering firm that focuses on biotherapeutics to treat cancer...Read More... The post BMS agrees to acquire biotherapeutics developer Forbius appeared first on Pharmaceutical Technology.

Read full article »
Forbius's Competitors | Forbius's News | Forbius's Financials
Stay up-to-date with the latest news on Forbius
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Ilia A Tikhomirov's photo - President & CEO of Forbius

President & CEO

Ilia A Tikhomirov

CEO Approval Rating

89/100

Read more
Stay up-to-date with the latest news on Forbius